Report cover image

Lysine specific demethylase 1 inhibitors - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18679740

Description

Lysine specific demethylase 1 inhibitors - Pipeline Insight, 2024



DelveInsight’s, “Lysine Specific Demethylase 1 (LSD-1) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Lysine Specific Demethylase 1 (LSD-1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Understanding

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview

Lysine-specific demethylase 1 (LSD1) was the first histone demethylase discovered and conserved from fission yeast (S. pombe) to mammals. LSD1 played a pivotal role in a variety of biological processes like cell proliferation, adipogenesis, spermatogenesis, chromosome segregation, pluripotency regulation of stem cell and embryonic development. The discovery of LSD1 in 2004 demonstrated for the first time that histone methylation is a reversible reaction. LSD1 has three structural domains that regulate its enzymatic activity and binding to several proteins. Upon specific stimulation, LSD1 can also act as a transcriptional co-activator. LSD1 is structurally similar to the Flavin-dependent monoamine oxidases (MAOs). Both LSD1 and MAOs utilize flavin adenine dinucleotide (FAD) as cofactor, thus, a number of known MAO inhibitors have been shown to also inhibit LSD1 through irreversible interaction of FAD. The overexpression of LSD1 is reported to be associated with different malignancies. Therefore, the inhibition of LSD1 provides a promising pharmacological target to investigate novel treatments for cancer and other disorders that associate with LSD1’s activity.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Lysine Specific Demethylase 1 (LSD-1) Inhibitor R&D. The therapies under development are focused on novel approaches for Lysine Specific Demethylase 1 (LSD-1) Inhibitor.
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Emerging Drugs Chapters

This segment of the Lysine Specific Demethylase 1 (LSD-1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Emerging Drugs
  • ORY-2001: Oryzon Genomics
ORY-1001 is an oral, brain-permeable small molecule. It is a dual inhibitor of the transcriptional co-regulator lysine-specific demethylase 1 (LSD1 or KDM1A) and the mitochondrial membrane protein monoamine oxidase B. The drug is in Phase II clinical studies for the treatment of Aggression, Alzheimer's disease, Borderline personality disorders, Multiple sclerosis, and SARS-CoV-2 acute respiratory disease.
  • Domatinostat: 4SC
Domatinostat is an orally administered small molecule for the treatment of cancer. The compound inhibits the enzymes histone deacetylase (HDAC) 1, 2, and 3, which are believed to play important roles in the regulation of aberrant cancer signaling. The drug is in Phase II clinical studies for the treatment of Gastrointestinal cancer; Merkel cell carcinoma and in Phase I/II clinical development for Malignant melanoma treatment.

Further product details are provided in the report……..

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Lysine Specific Demethylase 1 (LSD-1) Inhibitor
There are approx. 11+ key companies which are developing the Lysine Specific Demethylase 1 (LSD-1) Inhibitor. The companies which have their Lysine Specific Demethylase 1 (LSD-1) Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Oryzon Genomics.
  • Phases
DelveInsight’s report covers around 11+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Lysine Specific Demethylase 1 (LSD-1) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lysine Specific Demethylase 1 (LSD-1) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Report Insights
  • Lysine Specific Demethylase 1 (LSD-1) Inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs?
  • How many Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Lysine Specific Demethylase 1 (LSD-1) Inhibitor?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lysine Specific Demethylase 1 (LSD-1) Inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lysine Specific Demethylase 1 (LSD-1) Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Oryzon Genomics
  • 4SC
  • Salarius Pharmaceuticals
  • Celgene Corporation
  • Taiho Pharmaceutical
  • CSPC ZhongQi Pharmaceutical Technology
  • Beatica
  • Rasna Therapeutics
Key Products
  • ORY-2001
  • Domatinostat
  • ORY-3001
  • Seclidemstat
  • CC-90011
  • TAS-1440
  • SYHA-1807
  • Research programme: small molecule therapeutics
  • RASP-201

Table of Contents

60 Pages
Introduction
Executive Summary
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Lysine Specific Demethylase 1 (LSD-1) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Lysine Specific Demethylase 1 (LSD-1) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ORY-2001: Oryzon Genomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Seclidemstat: Salarius Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme - small molecule therapeutics: Beatica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Products
Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Unmet Needs
Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Market Drivers and Barriers
Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Future Perspectives and Conclusion
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Analyst Views
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us